CN Patent

CN114703184B — Lpa抑制剂及其用途

Assigned to Kylonova Xiamen Biopharma Co Ltd · Expires 2024-06-18 · 2y expired

What this patent protects

本申请涉及一种抑制LPA基因表达的RNA抑制剂或其药学上可接受的盐，其包含反义链的互补区，所述互补区包括至少12个连续核苷酸，其中所述反义链包含以下的核苷酸序列：SEQ ID NO.414‑418中任意一个或与其相差不超过3个核苷酸的序列。本申请的RNA抑制剂直接降解LPA mRNA，持续高效地抑制LPA基因表达，可用于治疗或/和预防LPA基因介导的相关的心脑血管疾病。

USPTO Abstract

本申请涉及一种抑制LPA基因表达的RNA抑制剂或其药学上可接受的盐，其包含反义链的互补区，所述互补区包括至少12个连续核苷酸，其中所述反义链包含以下的核苷酸序列：SEQ ID NO.414‑418中任意一个或与其相差不超过3个核苷酸的序列。本申请的RNA抑制剂直接降解LPA mRNA，持续高效地抑制LPA基因表达，可用于治疗或/和预防LPA基因介导的相关的心脑血管疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN114703184B
Jurisdiction
CN
Classification
—
Expires
2024-06-18
Drug substance claim
No
Drug product claim
No
Assignee
Kylonova Xiamen Biopharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.